{"url_path":"/sec/rkda/8-k/2026-05-14/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-223985-index.html","accession_number":"0001193125-26-223985","cik":"0001469443","ticker":"RKDA","issuer_name":"Arcadia Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1469443/0001193125-26-223985-index.html","primary_entity_key":"0001469443","primary_entity_name":"Arcadia Biosciences, Inc."},"word_count":189,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn May 14, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter of 2026. A copy of the press release is furnished as Exhibit 99.1, and the Company's financial information tables are furnished as Exhibit 99.2, to this Current Report on Form 8-K and are incorporated herein by reference.\n\n \n\nThe information furnished in this Form 8-K, the press release attached as Exhibit 99.1, and the financial information attached as Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02, in the press release attached as Exhibit 99.1, and in the financial information attached as Exhibit 99.2, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing."}